Lymphoma

Circulating tumor DNA found in blood plasma may help predict if the likelihood of relapse for patients with large B-cell lymphoma, according to recent research.

The use of convalescent plasma therapy in patients with blood cancers and COVID-19 was associated with an improvement in survival from the infection.

The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.

A recent webinar from the Lymphoma Research Foundation gave important advice for caregivers, including the importance of taking care of oneself.

Patients with blood cancers may be less likely to derive immunity from the COVID-19 vaccine, though antibody tests should not be the end-all-be-all in guiding their behavior.

Researchers are evaluating the safety and efficacy of zandelisib, an investigational cancer therapy, for the treatment of patients with marginal zone lymphoma and follicular lymphoma who have received at least two prior therapies.

Combining PI3 kinase inhibitors with BTK inhibitors can mitigate side effects traditionally seen with PI3 kinase inhibitors, according to recent research.

In this episode of the “CURE® Talks Cancer” podcast, Olympic triathlete Kevin McDowell discusses his cancer journey and shares some insight on his experiences at the Tokyo 2020 Olympics.

Adolescent and young adult patients are more represented than previously expected in clinical trials. However, their outcomes still lag behind the younger and older populations.

Blood cancer survivors are living longer than ever, making safe pain management an important concern.

In his new memoir, a patient with central nervous system lymphoma emphasizes the importance of a positive mindset and a strong support system.

Nina Luker, a healthy 25 year old, felt invincible. But she says that "naïve perspective was disrupted in a matter of hours."

Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

From a 90-year-old man’s 3,600-mile walk to raise money for children with cancer to the death of KISS and Cinderella keyboardist Gary Corbett, here’s what’s happening in the cancer landscape this week.

The FDA approval of Rylaze provides certain patients with leukemia and lymphoma with an on-demand treatment option since the only other approved therapy is currently undergoing a shortage.

Monjuvi and Revlimid attained extended remission and improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma.

One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year.

These findings, according to one of the study’s authors, demonstrate that Yescarta addresses an important unmet medical need for patients with relapsed/refractory follicular lymphoma.

In this episode of the “CURE® Talks Cancer” podcast, author Steve Kelley shares both the painful and positive moments of his journey with a rare cancer.

Treatment with the combination of Polivy, rituximab and lenalidomide safely conferred responses in patients with relapsed/refractory diffuse large B-cell lymphoma, with most patients still in remission at the study’s cutoff date.

Combination therapy with Aliqopa and rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma.

As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.

For patients with early-stage, unfavorable-risk Hodgkin lymphoma, this treatment option may allow for the reduction or elimination of radiotherapy in patients without malignant disease.

The FDA has approved Zynlonta (loncastuximab tesirine-lpyl) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).